Related Experiment Videos
Clinical evaluation of venlafaxine
1Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, USA.
Journal of Clinical Psychopharmacology
|June 1, 1996
Summary
Venlafaxine is an effective first-line depression treatment for various severities. Clinical trials confirm its efficacy in both hospitalized and outpatient settings, showing significant improvement over placebo.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Depression is a prevalent mood disorder requiring effective pharmacotherapy.
- Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has emerged as a significant treatment option.
Purpose of the Study:
- To review clinical trials assessing the efficacy of venlafaxine as a first-line antidepressant.
- To evaluate venlafaxine's effectiveness in both severely ill hospitalized patients and outpatients.
Main Methods:
- Two representative clinical trials were reviewed: one placebo-controlled (93 inpatients) and one active-controlled (224 outpatients).
- Efficacy was measured using standardized rating scales.
- Patient demographics and baseline scores were comparable within each trial.
Main Results:
- Venlafaxine demonstrated statistically significant antidepressant efficacy compared to placebo in both trials.
- In inpatients, venlafaxine showed a rapid onset of action and reduced comorbid anxiety symptoms.
- Outpatients experienced fewer anticholinergic side effects compared to tricyclic antidepressants, with nausea being a notable side effect.
Conclusions:
- Venlafaxine is confirmed as an effective first-line agent for managing depression across different patient populations.
- The findings support venlafaxine's utility in both inpatient and outpatient settings.
- Venlafaxine offers a favorable side effect profile compared to some traditional antidepressants.